Cite
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
MLA
Argilés, Guillem, et al. “A Randomised Phase 2 Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in Previously Treated Metastatic Colorectal Cancer Patients (REARRANGE Trial).” European Journal of Cancer (Oxford, England : 1990), vol. 177, Dec. 2022, pp. 154–63. EBSCOhost, https://doi.org/10.1016/j.ejca.2022.09.037.
APA
Argilés, G., Mulet, N., Valladares-Ayerbes, M., Viéitez, J. M., Grávalos, C., García-Alfonso, P., Santos, C., Tobeña, M., García-Paredes, B., Benavides, M., Cano, M. T., Loupakis, F., Rodríguez-Garrote, M., Rivera, F., Goldberg, R. M., Cremolini, C., Bennouna, J., Ciardiello, F., Tabernero, J. M., … Tabernero, J. (2022). A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). European Journal of Cancer (Oxford, England : 1990), 177, 154–163. https://doi.org/10.1016/j.ejca.2022.09.037
Chicago
Argilés, Guillem, Nuria Mulet, Manuel Valladares-Ayerbes, José M Viéitez, Cristina Grávalos, Pilar García-Alfonso, Cristina Santos, et al. 2022. “A Randomised Phase 2 Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in Previously Treated Metastatic Colorectal Cancer Patients (REARRANGE Trial).” European Journal of Cancer (Oxford, England : 1990) 177 (December): 154–63. doi:10.1016/j.ejca.2022.09.037.